Atika Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.54M Sell
97,000
-68,000
-41% -$7.06M 0.69% 40
2026
Q2
$16.1M Buy
165,000
+36,200
+28% +$3.16M 1.06% 26
2026
Q1
$10.8M Sell
128,800
-5,728
-4% -$332K 1.36% 22
2025
Q4
$5.54M Buy
+134,528
New +$5.22M 0.58% 50

Other funds holding DNTH

Atika Capital Management's DNTH Position: Q3 2026 in Review

Atika Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 41% in Q3 2026, selling an estimated $7.06M and leaving 97,000 shares worth $8.54M. The position accounts for 0.69% of the portfolio, ranked #40.

Atika Capital Management first reported a position in DNTH in Q4 2025 and has held it in 4 quarters since. The position peaked at $16.1M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Atika Capital Management held 97,000 shares of Dianthus Therapeutics worth $8.54M as of Q3 2026.
  • Atika Capital Management sold 68,000 Dianthus Therapeutics shares in Q3 2026, an estimated $7.06M.
  • Dianthus Therapeutics made up 0.69% of Atika Capital Management's portfolio in Q3 2026, its #40 holding.
  • Atika Capital Management first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Atika Capital Management's Dianthus Therapeutics position peaked at $16.1M in Q2 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Atika Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.